Trial Profile

A Phase 3 Randomized, Double-blind, Placebo-controlled Multicenter Study to Evaluate the Efficacy and Safety of Remdesivir in Hospitalized Adult Patients With Mild and Moderate COVID-19.

Status: Suspended

Phase of Trial: Phase III

Latest Information Update: 27 Sep 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Remdesivir (Primary)
Indications COVID 2019 infections
Focus Therapeutic Use

Most Recent Events

10 Mar 2021 Results (n=1005) assessing whether remdesivir was associated with worsening renal function in hospitalized patients with moderate COVID-19, presented at the 28th Conference on Retroviruses and Opportunistic Infections
25 Oct 2020 Results (n=584) presented at the IDWeek 2020
13 Apr 2020 Status changed from recruiting to suspended.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com